Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of carboplatin + pemetrexed + bevacizumab + erlotinib in EGFR-mutated advanced non-squamous NSCLC
jRCTs031180157Phase 2Completed
- Sponsor
- North East Japan Study Group
- Start
- Nov 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, pemetrexed, bevacizumab and erlotinib in non-small cell lung cancer (NSCLC), sponsored by North East Japan Study Group. Primary endpoint: Progression-free survival. Started Nov 2017; status: completed.
02
Drugs
carboplatinpemetrexedbevacizumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031180157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180157.